Treatment outcomes of advanced digestive well-differentiated grade 3 NETs
Authorsde Mestier, L.
Walenkamp, A. M. E.
Van Velthuysen, M. F.
García Gómez-Muriel, M. I.
Pavel, M. E
AffiliationL de Mestier, Gastroenterology and Pancreatology, Hopital Beaujon, Clichy, France.
MetadataShow full item record
AbstractThere is no standardized treatment for grade 3 neuroendocrine tumors (G3 NETs). We aimed to describe the treatments received in patients with advanced G3 NETs and compare their efficacy. Patients with advanced digestive G3 NETs treated between 2010 and 2018 in seven expert centers were retrospectively studied. Pathological samples were centrally reviewed, and radiological data were locally reviewed. We analyzed RECIST-defined objective response (OR), tumor growth rate (TGR) and progression-free survival (PFS) obtained with first- (L1) or second-line (L2) treatments. We included 74 patients with advanced G3 NETs, mostly from duodenal or pancreatic origin (71.6%), with median Ki-67 of 30%. The 126 treatments (L1=74; L2=52) included alkylating-based (n=32), etoposide-platinum (n=22) or adenocarcinoma-like chemotherapy (n=20), somatostatin analogs (n=21), targeted therapies (n=22) and liver-directed therapies (n=7). Alkylating-based chemotherapy achieved the highest OR rate (37.9%) compared to other treatments (multivariable OR 4.22, 95% CI [1.5-12.2]; p=0.008). Adenocarcinoma-like and alkylating-based chemotherapies showed the highest reductions in 3-month TGR (p<0.001 and p=0.008, respectively). The longest median PFS were obtained with adenocarcinoma-like chemotherapy (16.5 months [9.0-24.0]) and targeted therapies (12.0 months [8.2-15.8]), while the shortest PFS were observed with somatostatin analogues (6.2 months [3.8-8.5]) and etoposide-platinum chemotherapy (7.2 months [5.2-9.1]). Etoposide-platinum CT achieved shorter PFS than adenocarcinoma-like (multivariable HR 3.69 [1.61-8.44], p=0.002) and alkylating-based chemotherapies (multivariable HR 1.95 [1.01-3.78], p=0.049). Overall, adenocarcinoma-like and alkylating-based chemotherapies may be the most effective treatments for patients with advanced G3 NETs regarding OR and PFS. Etoposide-platinum chemotherapy has poor efficacy in this setting.
Citationde Mestier L, Lamarca A, Hernando J, Zandee W, Alonso-Gordoa T, Perrier M, et al. Treatment outcomes of advanced digestive well-differentiated grade 3 NETs. Endocrine-Related Cancer. 2021 Jun.
JournalEndocrine Related Cancer
- Heterogeneity of grade 3 gastroenteropancreatic neuroendocrine carcinomas: New insights and treatment implications.
- Authors: Fazio N, Milione M
- Issue date: 2016 Nov
- Characteristics and treatment of patients with G3 gastroenteropancreatic neuroendocrine neoplasms.
- Authors: Heetfeld M, Chougnet CN, Olsen IH, Rinke A, Borbath I, Crespo G, Barriuso J, Pavel M, O'Toole D, Walter T, other Knowledge Network members.
- Issue date: 2015 Aug
- Value of Tumor Growth Rate (TGR) as an Early Biomarker Predictor of Patients' Outcome in Neuroendocrine Tumors (NET)-The GREPONET Study.
- Authors: Lamarca A, Crona J, Ronot M, Opalinska M, Lopez Lopez C, Pezzutti D, Najran P, Carvhalo L, Franca Bezerra RO, Borg P, Vietti Violi N, Vidal Trueba H, de Mestier L, Schaefer N, Sundin A, Costa F, Pavel M, Dromain C, Knowledge Network.
- Issue date: 2019 Nov
- 177Lu-DOTATATE therapy in patients with neuroendocrine tumours including high-grade (WHO G3) neuroendocrine tumours: response to treatment and long-term survival update.
- Authors: Demirci E, Kabasakal L, Toklu T, Ocak M, Şahin OE, Alan-Selcuk N, Araman A
- Issue date: 2018 Aug
- Peptide Receptor Radionuclide Therapy in Grade 3 Neuroendocrine Neoplasms: Safety and Survival Analysis in 69 Patients.
- Authors: Zhang J, Kulkarni HR, Singh A, Niepsch K, Müller D, Baum RP
- Issue date: 2019 Mar